Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based immunotherapy company PDS Biotechnology has partnered with Brazilian biotechnology firm Farmacore Biotechnology to jointly develop a Covid-19 vaccine.
The vaccine candidate, Versamune-CoV-2FC (PDS0204), is based on PDS Biotechnology’s immune-activating Versamune platform, integrating a recombinant fusion protein of SARS-CoV-2 developed by Farmacore to be recognised by the human immune system.
The vaccine is expected to rapidly trigger neutralising antibodies, killer T-cells and memory T-cells against the SARS-CoV-2 virus.